CHI3L1 and LCN2, two immune-related biomarkers used for monitoring intraductal tumor progression (3, 4) and breast cancer patient prognosis (22–24), confirmed the differential tumor progression and immunology with differential levels in spleens, primary tumors and serum of both models. This evidence concerns the gene LCN2 and breast carcinoma.